Search | VHL Search Portal

1.

Host genetic variability and determinants of severe COVID-19.

Brest, Patrick; Mograbi, Baharia; Gal, Jocelyn; Hofman, Paul; Milano, Gerard.

Trends Genet ; 39(3): 169-171, 2023 03.

Article in English | MEDLINE | ID: mdl-36379742

2.

Using Genetics To Dissect SARS-CoV-2 Infection.

Brest, Patrick; Mograbi, Baharia; Hofman, Paul; Milano, Gerard.

Trends Genet ; 37(3): 203-204, 2021 03.

Article in English | MEDLINE | ID: mdl-33309104

3.

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.

Le Teuff, Gwénaël; Cozic, Nathalie; Boyer, Jean-Christophe; Boige, Valérie; Diasio, Robert B; Taieb, Julien; Meulendijks, Didier; Palles, Claire; Schwab, Matthias; Deenen, Maarten; Largiadèr, Carlo R; Marinaki, Anthony; Jennings, Barbara A; Wettergren, Yvonne; Di Paolo, Antonello; Gross, Eva; Budai, Barna; Ackland, Stephen P; van Kuilenburg, André B P; McLeod, Howard L; Milano, Gérard; Thomas, Fabienne; Loriot, Marie-Anne; Kerr, David; Schellens, Jan H M; Laurent-Puig, Pierre; Shi, Qian; Pignon, Jean-Pierre; Etienne-Grimaldi, Marie-Christine.

Br J Cancer ; 130(5): 808-818, 2024 Mar.

Article in English | MEDLINE | ID: mdl-38225422

4.

Molecular and nutritional markers in head and neck cancer.

Milano, Gerard; Gal, Jocelyn; Bensadoun, René-Jean.

Curr Opin Oncol ; 36(3): 123-127, 2024 May 01.

Article in English | MEDLINE | ID: mdl-38441194

5.

Host Polymorphisms May Impact SARS-CoV-2 Infectivity.

Brest, Patrick; Refae, Sadal; Mograbi, Baharia; Hofman, Paul; Milano, Gerard.

Trends Genet ; 36(11): 813-815, 2020 11.

Article in English | MEDLINE | ID: mdl-32828550

6.

Checkpoint inhibitors and anti-angiogenic agents: a winning combination.

Brest, Patrick; Mograbi, Baharia; Pagès, Gilles; Hofman, Paul; Milano, Gerard.

Br J Cancer ; 129(9): 1367-1372, 2023 10.

Article in English | MEDLINE | ID: mdl-37735244

7.

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.

Milano, Gérard; Innocenti, Federico; Minami, Hironobu.

Cancer Sci ; 113(7): 2224-2231, 2022 Jul.

Article in English | MEDLINE | ID: mdl-35445479

8.

COVID-19 vaccination and cancer immunotherapy: should they stick together?

Brest, Patrick; Mograbi, Baharia; Hofman, Paul; Milano, Gerard.

Br J Cancer ; 126(1): 1-3, 2022 01.

Article in English | MEDLINE | ID: mdl-34799696

9.

Checkpoint inhibitors in a marriage: consented or arranged?

Brest, Patrick; Refae, Sadal; Mograbi, Baharia; Ferrero, Jean-Marc; Bontoux, Christophe; Hofman, Paul; Milano, Gerard.

Br J Cancer ; 126(12): 1834-1836, 2022 06.

Article in English | MEDLINE | ID: mdl-35523880

10.

More light on cancer and COVID-19 reciprocal interaction.

Brest, Patrick; Mograbi, Baharia; Hofman, Paul; Milano, Gerard.

Br J Cancer ; 124(8): 1344-1345, 2021 04.

Article in English | MEDLINE | ID: mdl-33531686

11.

COVID-19 vaccine race: watch your step for cancer patients.

Fanciullino, Raphaelle; Ciccolini, Joseph; Milano, Gerard.

Br J Cancer ; 124(5): 860-861, 2021 03.

Article in English | MEDLINE | ID: mdl-33288844

12.

Optimizing drug development in oncology by clinical trial simulation: Why and how?

Gal, Jocelyn; Milano, Gérard; Ferrero, Jean-Marc; Saâda-Bouzid, Esma; Viotti, Julien; Chabaud, Sylvie; Gougis, Paul; Le Tourneau, Christophe; Schiappa, Renaud; Paquet, Agnes; Chamorey, Emmanuel.

Brief Bioinform ; 19(6): 1203-1217, 2018 11 27.

Article in English | MEDLINE | ID: mdl-28575140

13.

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.

Refae, Sadal; Gal, Jocelyn; Ebran, Nathalie; Otto, Josiane; Borchiellini, Delphine; Peyrade, Frederic; Chamorey, Emmanuel; Brest, Patrick; Milano, Gérard; Saada-Bouzid, Esma.

Invest New Drugs ; 38(1): 160-171, 2020 02.

Article in English | MEDLINE | ID: mdl-31402427

14.

DPD status and fluoropyrimidines-based treatment: high activity matters too.

Chamorey, Emmanuel; Francois, Eric; Etienne, Marie-Christine; Ferrero, Jean-Marc; Peyrade, Frederic; Barranger, Emmanuel; Bozec, Alexandre; Largillier, Rémy; Cassuto, Ophelie; Viotti, Julien; Schiappa, Renaud; Milano, Gérard.

BMC Cancer ; 20(1): 436, 2020 May 18.

Article in English | MEDLINE | ID: mdl-32423482

15.

Immune check points in cancer treatment: current challenges and perspectives.

Ciccolini, Joseph; Milano, Gerard.

Br J Cancer ; 129(9): 1365-1366, 2023 10.

Article in English | MEDLINE | ID: mdl-37898723

16.

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).

Lévi, Francis; Karaboué, Abdoulaye; Saffroy, Raphaël; Desterke, Christophe; Boige, Valerie; Smith, Denis; Hebbar, Mohamed; Innominato, Pasquale; Taieb, Julien; Carvalho, Carlos; Guimbaud, Rosine; Focan, Christian; Bouchahda, Mohamed; Adam, René; Ducreux, Michel; Milano, Gérard; Lemoine, Antoinette.

Br J Cancer ; 117(7): 965-973, 2017 Sep 26.

Article in English | MEDLINE | ID: mdl-28817838

17.

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Dufies, Maeva; Giuliano, Sandy; Viotti, Julien; Borchiellini, Delphine; Cooley, Linsay S; Ambrosetti, Damien; Guyot, Mélanie; Ndiaye, Papa Diogop; Parola, Julien; Claren, Audrey; Schiappa, Renaud; Gal, Jocelyn; Frangeul, Antoine; Jacquel, Arnaud; Cassuto, Ophélie; Grépin, Renaud; Auberger, Patrick; Bikfalvi, Andréas; Milano, Gérard; Escudier, Bernard; Rioux-Leclercq, Nathalie; Porta, Camillo; Negrier, Sylvie; Chamorey, Emmanuel; Ferrero, Jean-Marc; Pagès, Gilles.

Br J Cancer ; 117(7): 947-953, 2017 Sep 26.

Article in English | MEDLINE | ID: mdl-28850564

18.

Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.

Lattanzio, Laura; Denaro, Nerina; Vivenza, Daniela; Varamo, Chiara; Strola, Giuliana; Fortunato, Mirella; Chamorey, Emmanuel; Comino, Alberto; Monteverde, Martino; Lo Nigro, Cristiana; Milano, Gerard; Merlano, Marco.

Cancer Immunol Immunother ; 66(5): 573-579, 2017 May.

Article in English | MEDLINE | ID: mdl-28197666

19.

Resistance to immunotherapy: clouds in a bright sky.

Milano, Gérard.

Invest New Drugs ; 35(5): 649-654, 2017 10.

Article in English | MEDLINE | ID: mdl-28401366

20.

Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.

Refae, Sadal; Gal, Jocelyn; Ebran, Nathalie; Otto, Josiane; Borchiellini, Delphine; Peyrade, Frederic; Chamorey, Emmanuel; Brest, Patrick; Milano, Gérard; Saada-Bouzid, Esma.

Invest New Drugs ; 39(1): 287-292, 2021 Feb.

Article in English | MEDLINE | ID: mdl-32500464

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export:

Host genetic variability and determinants of severe COVID-19.

Using Genetics To Dissect SARS-CoV-2 Infection.

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.

Molecular and nutritional markers in head and neck cancer.

Host Polymorphisms May Impact SARS-CoV-2 Infectivity.

Checkpoint inhibitors and anti-angiogenic agents: a winning combination.

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.

COVID-19 vaccination and cancer immunotherapy: should they stick together?

Checkpoint inhibitors in a marriage: consented or arranged?

More light on cancer and COVID-19 reciprocal interaction.

COVID-19 vaccine race: watch your step for cancer patients.

Optimizing drug development in oncology by clinical trial simulation: Why and how?

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.

DPD status and fluoropyrimidines-based treatment: high activity matters too.

Immune check points in cancer treatment: current challenges and perspectives.

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.

Resistance to immunotherapy: clouds in a bright sky.

Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.